Definium Therapeutics Announces Topline Results From Phase 3 Voyage Study Of DT120 ODT In Generalized Anxiety Disorder; Study Met Primary And All Key Secondary Efficacy Endpoints
Topline results from Voyage, its first Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults with generalized anxiety disorder (GAD). The results mark the Company’s second positive DT120
Definium's anxiety medicine passed its big test, showing it works better than a fake pill. When a medicine passes an important test like this, it's a step closer to helping real patients, so it's something to watch as the company moves forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.